Development of HSP90 inhibitors-SN38 conjugates for cancer treatment

Cao, Yuting; Shen, Qianqian; Ding, Mengyuan; Chen, Yi; Lü, Wei; Zhu, Shulei

doi:10.1016/j.bioorg.2023.106582

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PEN-866 is an ADC that specifically targets intracellular Heat Shock Protein 90 (HSP90) and carries the topoisomerase 1 inhibitor SN-38 as a payload. PEN-866 demonstrated preliminary evidence of antitumor activity in preclinical models and in a phase I clinical trial [53,54].…”

Section: Future Perspectivesmentioning

confidence: 99%

Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates

Belluomini,

Sposito,

Avancini

et al. 2023

Cancers

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) is a highly aggressive disease, accounting for about 15% of all lung cancer cases. Despite initial responses to chemoimmunotherapy, SCLC recurs and becomes resistant to treatment. Recently, antibody–drug conjugates (ADCs) have emerged as a promising therapeutic option for SCLC. ADCs consist of an antibody that specifically targets a tumor antigen linked to a cytotoxic drug. The antibody delivers the drug directly to the cancer cells, minimizing off-target toxicity and improving the therapeutic index. Several ADCs targeting different tumor antigens are currently being evaluated in clinical trials for SCLC. Despite the negative results of rovalpituzumab tesirine (Rova-T), other ADCs targeting different antigens, such as B7-H3, seizure-related homolog 6 (SEZ6), and CEACAM5, have also been investigated in clinical trials, including for SCLC, and their results suggest preliminary activity, either alone or in combination with other therapies. More recently, sacituzumab govitecan, an anti-TROP2 ADC, demonstrated promising activity in lung cancer, including SCLC. Furthermore, an anti-B7-H3 (CD276), ifinatamab deruxtecan (DS7300A), showed a high response rate and durable responses in heavily pretreated SCLC. Overall, ADCs represent an intriguing approach to treating SCLC, particularly in the relapsed or refractory setting. Further studies are needed to determine their efficacy and safety and the best location in the treatment algorithm for SCLC. In this review, we aim to collect and describe the results regarding the past, the present, and the future of ADCs in SCLC.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%